Disease characteristics at presentation for WM patients stratified by MYD88 and NS and FS CXCR4 mutation status
| . | MYD88WTCXCR4WT . | MYD88L265PCXCR4WT . | MYD88L265PCXCR4WHIM/FS . | MYD88L265PCXCR4WHIM/NS . | P . |
|---|---|---|---|---|---|
| n | 15 | 109 | 24 | 26 | |
| Gender (M/F) | 7/8 | 73/36 | 14/10 | 17/9 | – |
| Age (years) | 66 (42-82) | 59 (40-88) | 62 (34-88) | 59 (41-75) | .05 |
| BM involvement (%) | 15 (5-65) | 40 (5-95) | 37 (5-90) | 50 (15-95) | <.01 |
| Abs neutrophil (k/μL) | 2.93 (0.72-3.7) | 3.5 (1.04-8.94) | 3.54 (1.52-8.2) | 3.1 (1.56-6.14) | .01 |
| Abs lymphocyte (k/μL) | 1.61 (0.8-17.3) | 1.73 (0.48-11.1) | 1.77 (0.96-3.55) | 1.63 (0.51-3.88) | – |
| Hemoglobin (g/dL) | 11.3 (8-14.4) | 11.5 (6-15.5) | 11.8 (4.8-15.6) | 11.5 (6.2-14.2) | – |
| Platelet (k/μL) | 218 (105-378) | 274 (75-512) | 275 (101-441) | 208 (42-314) | <.01 |
| Serum IgA (mg/dL) | 140 (27-324) | 61 (0-1240) | 45 (20-202) | 45 (7-864) | – |
| Serum IgG (mg/dL) | 734 (441-1480) | 686 (138-2920) | 612 (267-978) | 569 (168-1330) | – |
| Serum IgM (mg/dL) | 2720 (134-5810) | 3190 (345-8720) | 2895 (416-8320) | 5200 (804-8767) | <.01 |
| B2M (mg/L) | 3.1 (2-5.5) | 3.1 (1.4-10.4) | 2.45 (1.4-9.2) | 2.4 (1-5) | – |
| Adenopathy | 6 (40%) | 59 (54.1%) | 7 (29.2%) | 8 (30.1%) | .04 |
| Splenomegaly | 6 (40%) | 18 (16.5%) | 2 (8.3%) | 6 (23.1%) | – |
| Family history | 4 (26.7%) | 31(28.4%) | 9 (37.5%) | 11 (42.3%) | – |
| Prior MGUS history | 4 (26.6%) | 18 (16.5%) | 5 (20.8%) | 3 (11.5%) | – |
| Symptomatic disease | 9 (60%) | 69 (63.3%) | 11 (45.8%) | 22 (84.6%) | .03 |
| Hyperviscosity syndrome | 0 (0%) | 10 (9.2%) | 2 (8.3%) | 8 (30.7%) | .01 |
| . | MYD88WTCXCR4WT . | MYD88L265PCXCR4WT . | MYD88L265PCXCR4WHIM/FS . | MYD88L265PCXCR4WHIM/NS . | P . |
|---|---|---|---|---|---|
| n | 15 | 109 | 24 | 26 | |
| Gender (M/F) | 7/8 | 73/36 | 14/10 | 17/9 | – |
| Age (years) | 66 (42-82) | 59 (40-88) | 62 (34-88) | 59 (41-75) | .05 |
| BM involvement (%) | 15 (5-65) | 40 (5-95) | 37 (5-90) | 50 (15-95) | <.01 |
| Abs neutrophil (k/μL) | 2.93 (0.72-3.7) | 3.5 (1.04-8.94) | 3.54 (1.52-8.2) | 3.1 (1.56-6.14) | .01 |
| Abs lymphocyte (k/μL) | 1.61 (0.8-17.3) | 1.73 (0.48-11.1) | 1.77 (0.96-3.55) | 1.63 (0.51-3.88) | – |
| Hemoglobin (g/dL) | 11.3 (8-14.4) | 11.5 (6-15.5) | 11.8 (4.8-15.6) | 11.5 (6.2-14.2) | – |
| Platelet (k/μL) | 218 (105-378) | 274 (75-512) | 275 (101-441) | 208 (42-314) | <.01 |
| Serum IgA (mg/dL) | 140 (27-324) | 61 (0-1240) | 45 (20-202) | 45 (7-864) | – |
| Serum IgG (mg/dL) | 734 (441-1480) | 686 (138-2920) | 612 (267-978) | 569 (168-1330) | – |
| Serum IgM (mg/dL) | 2720 (134-5810) | 3190 (345-8720) | 2895 (416-8320) | 5200 (804-8767) | <.01 |
| B2M (mg/L) | 3.1 (2-5.5) | 3.1 (1.4-10.4) | 2.45 (1.4-9.2) | 2.4 (1-5) | – |
| Adenopathy | 6 (40%) | 59 (54.1%) | 7 (29.2%) | 8 (30.1%) | .04 |
| Splenomegaly | 6 (40%) | 18 (16.5%) | 2 (8.3%) | 6 (23.1%) | – |
| Family history | 4 (26.7%) | 31(28.4%) | 9 (37.5%) | 11 (42.3%) | – |
| Prior MGUS history | 4 (26.6%) | 18 (16.5%) | 5 (20.8%) | 3 (11.5%) | – |
| Symptomatic disease | 9 (60%) | 69 (63.3%) | 11 (45.8%) | 22 (84.6%) | .03 |
| Hyperviscosity syndrome | 0 (0%) | 10 (9.2%) | 2 (8.3%) | 8 (30.7%) | .01 |
This table denotes comparisons of patient characteristics at diagnosis delineated by NS and FS CXCR4 mutation status.
Abs, absolute; –, not significant.